Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
January 29, 2025 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
January 13, 2025 08:00 ET
|
Cabaletta Bio
– Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and...
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
November 26, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
November 18, 2024 07:00 ET
|
Cabaletta Bio
– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – –...
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
November 14, 2024 07:00 ET
|
Cabaletta Bio
– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR...
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 06, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
September 25, 2024 16:30 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
August 28, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024 07:00 ET
|
Cabaletta Bio
– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling – – Additional clinical...
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
July 02, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...